Bronchopulmonary Dysplasia Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Act ion, Route of Administration by DelveInsight | MEDIPOST Co., Ltd

The Bronchopulmonary Dysplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Bronchopulmonary Dysplasia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchopulmonary Dysplasia Market.

Some of the key takeaways from the Bronchopulmonary Dysplasia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Bronchopulmonary Dysplasia treatment therapies with a considerable amount of success over the years. 
• Bronchopulmonary Dysplasia companies working in the treatment market are AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, MEDIPOST Co., Ltd., Oak Hill Bio Ltd, Mallinckrodt, and others, are developing therapies for the Bronchopulmonary Dysplasia treatment 

• Emerging Bronchopulmonary Dysplasia therapies in the different phases of clinical trials are-  AVR-48, AT-100, UMC119-01, PNEUMOSTEM, OHB-607, INOmax, and others are expected to have a significant impact on the Bronchopulmonary Dysplasia market in the coming years.   
• In June 2019, The “Treatment of Delayed Pulmonary Transition in ExtremelyPreterm Infants & Bronchopulmonary Dysplasia” experiment was started by Mallinckrodt. To assess the impact of inhaled nitric oxide on the outcome of survival and incidence of bronchopulmonary dysplasia, a single centre, blinded, randomised control clinical trial is being conducted
• High-dose omega-3 docosahexaenoic acid (DHA) supplementation has been shown to increase the risk of bronchopulmonary dysplasia (BPD) and improve IQ in children born at less than 29 weeks gestation.

Bronchopulmonary Dysplasia Overview

Infants with bronchopulmonary dysplasia (BPD), a kind of chronic lung illness that frequently affects preterm babies who require oxygen therapy, are affected. BPD causes tissue deterioration (dysplasia) in the tiny air sacs of the lung, or alveoli, as a result of injury to the lungs and the airways (bronchi). In the US, between 10,000 and 15,000 infants are thought to experience BPD annually.

Get a Free Sample PDF Report to know more about Bronchopulmonary Dysplasia Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight

Emerging Bronchopulmonary Dysplasia Drugs Under Different Phases of Clinical Development Include:

• AVR-48: AyuVis Research
• AT-100: Airway Therapeutics, Inc
• UMC119-01: Meridigen Biotechnology
• PNEUMOSTEM: MEDIPOST Co., Ltd.
• OHB-607: Oak Hill Bio Ltd
• INOmax: Mallinckrodt

Route of Administration

Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment

• Bronchopulmonary Dysplasia Assessment by Product Type
• Bronchopulmonary Dysplasia By Stage and Product Type
• Bronchopulmonary Dysplasia Assessment by Route of Administration
• Bronchopulmonary Dysplasia By Stage and Route of Administration
• Bronchopulmonary Dysplasia Assessment by Molecule Type
• Bronchopulmonary Dysplasia by Stage and Molecule Type

DelveInsight’s Bronchopulmonary Dysplasia Report covers around 12+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bronchopulmonary Dysplasia product details are provided in the report. Download the Bronchopulmonary Dysplasia pipeline report to learn more about the emerging Bronchopulmonary Dysplasia therapies

Some of the key companies in the Bronchopulmonary Dysplasia Therapeutics Market include:

Key companies developing therapies for Bronchopulmonary Dysplasia are – MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc, Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.

Bronchopulmonary Dysplasia Pipeline Analysis:

The Bronchopulmonary Dysplasia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.
• Bronchopulmonary Dysplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bronchopulmonary Dysplasia drugs and therapies

Bronchopulmonary Dysplasia Pipeline Market Drivers

• Increased Research and Development Activities, new and developed Robust Pipeline are some of the important factors that are fueling the Bronchopulmonary Dysplasia Market.

Bronchopulmonary Dysplasia Pipeline Market Barriers

• However, complications with available treatment options, no Approved therapy, lack of a reliable methods for identifying pediatric patients at risk and other factors are creating obstacles in the Bronchopulmonary Dysplasia Market growth.

Scope of Bronchopulmonary Dysplasia Pipeline Drug Insight    

• Coverage: Global
• Key Bronchopulmonary Dysplasia Companies: AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, MEDIPOST Co., Ltd., Oak Hill Bio Ltd, Mallinckrodt, and others
• Key Bronchopulmonary Dysplasia Therapies: AVR-48, AT-100, UMC119-01, PNEUMOSTEM, OHB-607, INOmax, and others
• Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies
• Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers 

Request for Sample PDF Report for Bronchopulmonary Dysplasia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services